- Home
- CALX vs AKRO Comparison
CALX vs AKRO Comparison
Compare CALX & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CALX
- AKRO
- Stock Information
- Founded
- CALX 1999
- AKRO 2017
- Country
- CALX United States
- AKRO United States
- Employees
- CALX N/A
- AKRO N/A
- Industry
- CALX Telecommunications Equipment
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- CALX Consumer Discretionary
- AKRO Health Care
- Exchange
- CALX Nasdaq
- AKRO Nasdaq
- Market Cap
- CALX 2.4B
- AKRO 2.1B
- IPO Year
- CALX 2010
- AKRO 2019
- Fundamental
- Price
- CALX $37.11
- AKRO $31.59
- Analyst Decision
- CALX Strong Buy
- AKRO Strong Buy
- Analyst Count
- CALX 6
- AKRO 7
- Target Price
- CALX $42.50
- AKRO $43.20
- AVG Volume (30 Days)
- CALX 368.7K
- AKRO 441.5K
- Earning Date
- CALX 10-28-2024
- AKRO 11-11-2024
- Dividend Yield
- CALX N/A
- AKRO N/A
- EPS Growth
- CALX N/A
- AKRO N/A
- EPS
- CALX N/A
- AKRO N/A
- Revenue
- CALX $890,128,000.00
- AKRO N/A
- Revenue This Year
- CALX N/A
- AKRO N/A
- Revenue Next Year
- CALX $4.01
- AKRO N/A
- P/E Ratio
- CALX N/A
- AKRO N/A
- Revenue Growth
- CALX N/A
- AKRO N/A
- 52 Week Low
- CALX $26.76
- AKRO $11.36
- 52 Week High
- CALX $45.15
- AKRO $37.00
- Technical
- Relative Strength Index (RSI)
- CALX 50.00
- AKRO 66.34
- Support Level
- CALX $36.89
- AKRO $29.34
- Resistance Level
- CALX $40.41
- AKRO $32.15
- Average True Range (ATR)
- CALX 1.16
- AKRO 1.26
- MACD
- CALX -0.08
- AKRO 0.10
- Stochastic Oscillator
- CALX 34.89
- AKRO 99.74
About CALX Calix Inc
Calix Inc develops, market and sell Calix cloud, systems and software platforms to enable service providers of all types and sizes to innovate and transform. The company's customers utilize the real-time data and insights from Calix platforms to simplify their business and deliver experiences that excite their subscribers. The resulting growth in subscriber acquisition, loyalty and revenue creates more value for their businesses and communities. The Company's revenue is principally derived in the United States and it also has its presence in Middle East & Africa, Europe, Asia Pacific and other markets.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.